Bayer Cipro gets pediatric exclusivity
Executive Summary
Bayer Cipro market exclusivity extended until June 9 after FDA grants six-month pediatric extension Dec. 18. Pediatric approval is based on 689-patient Cipro comparative trial; five-year, 1,029-patient observational study; and pharmacokinetic analysis. Although Bayer's patent expired Dec. 9, the product was protected by a 90-day review grace period following the Sept. 24 submission of the exclusivity application. Barr will continue to market its "authorized" ciprofloxacin generic through the pediatric exclusivity period (1"The Pink Sheet" Sept. 29, 2003, In Brief)...
You may also be interested in...
Ortho Tri-Cyclen Pediatric Precaution Data Will Be Added To Label
Ortho-McNeil is changing labeling for Ortho Tri-Cyclen to include information from its pediatric exclusivity study showing lack of significant effect on low mineral bone density in anorexic adolescent females
Barr ciprofloxacin marketing continues
Barr will continue to market authorized generic of Bayer's antibiotic Cipro (ciprofloxacin) during the product's expected pediatric exclusivity, which runs for six months beginning Dec. 9, under an amended agreement. Barr had a similar deal on AstraZeneca's breast cancer drug Nolvadex (tamoxifen) but was forced to drop its authorized generic during the pediatric exclusivity period (1"The Pink Sheet" Feb. 3, 2003, p. 13)...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.